

ANTI-PSORIASIS EFFICACY TESTING FOR TOPICAL APPLICATION

Genoskin helps evaluate the efficacy of anti-psoriasis drugs & compounds using its unique InflammoSkin® psoriasis skin model. Our ex vivo drug efficacy studies can be conducted for anti-psoriasis treatments that are designed for prophylactic or therapeutic use.

Topical InflammoSkin® services

Our **data generation platform** uses a live ex vivo human skin model featuring **resident T-cell activation** and a **Th17/Th1 phenotype**. It offers a 7 day experimental window to evaluate the efficacy of topical anti-psoriasis formula.



How we generate data to evaluate the efficacy of your anti-psoriasis molecule

Skin inflammation

Th17/Th1 activation through multiplex analysis of cytokine release
(see figures below)




Tissue integrity & epidermal activation

histological analysis of psoriasis specific markers

Spatial biology

MANTIS®, a multiplex imaging solution dedicated to immune cells profiling in skin

Pharmacological response to InflammoSkin® treatment with betamethasone dipropionate gel (BDP gel) and phosphodiesterase inhibitor (PDE4-inh) applied topically and daily for 7 days



Case Study

Calcipotriol/Betamethasone Dipropionate Foam inhibits Th17 Cytokine Secretion and Improves Epidermal Barrier markers in a Human Th17 Inflammation Model
Lovato, Paola et al. Dermatology and therapy vol.11,1(2021): 265-274. doi:10.1007/s13555-020-00482-9

www.genoskin.com

